Tuesday, June 18, 2019 6:08:57 PM
I was lucky enough to be able to talk to Dr Talor and he has kindly offered to answer some of my questions.
So I am happy to share with the community today with the best of my understanding and my own words, sorry M. Talor if the wording is not as precise as it should be.
First of all he confirmed that despite the study was open labelled they were completely blinded.
He said IDMC should meet in general every 6 months, provided that there is enough to be discussed /analysed between two meetings.
Regarding 3 Years survival, he said that the nature of the tumor being treated (most in % is dealing with oral cavity) plus the staging (Inclusion criteria) made it eligible for the low-end survival numbers for Head and Neck cancer (in general H&N survival statistics given in literature talk about relative survival for a blend of lips, tongue, soft palate etc…which is better then what it should be from this Clinical Trial). He confirmed again that 298 includes all kind of deaths, therefore survivors are “overall survivors” and not “relative survivors”
He said :
- Survival hope at 3 years has not increased much for this specific cancer location over the years
- HPV do not impact much this zone of the mouth and therefore should not influence survival either
- No chance than Checkpoint inhibitors have had time to improve SOC from 2011 to 2016 in particular in the regions where the CT took place
He said dropouts should be contained as no more patients than the initial design were required to get statistical significance
Having all this in mind, he said that the fact that most of patients have been treated more than 3years ago (some more than 7 years) and 298 not being reached shows a survival pattern that is in not in accordance with what should be expected from SoC alone. (Personal note : This point is the main evidence given by the models that we have run so far that tend to prove that the drug is efficient)
On the question of Primary Endpoint : he said it was Event driven and not Time driven (as I suspected). They have to wait for 298 and then they compare survival in two arms and there is the need to show 10% Overall Survival improvement in MK arm. Average 3 years simply means the time they though 298 would be reached when they designed the study. Timeframe is required for Secondary endpoints such as Progression free survival, QoL etc…
Finally on the question on why this Science would work while every research seems to focus on Treg inhibidors : he simply said because he saw it work on more than 200 cases in prior studies ! He said that the fact that they treat prior SoC on an intact immune system without delaying SoC is a key point in the success of the drug that is being considered seriously now by some research oncologist and should be an eye opening if CT is successful.
Bottom line and my personal conclusion :
---------------------------------------------------
All the models ran so fast, based on time it takes to reach 298 event indicate that there is some efficacy shown in the MK arm. Most models show a strong efficacy over 10%. This discussion with Dr Talor only reinforces this feeling as it emphasizes the fact that survival expectancy is still poor for this category of patients treated with SoC.
I hope my transcript is a faithful reflection of what has been discussed, overall, do your own DD, make your own decisions.
Fosco
Recent CVM News
- CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population • Business Wire • 06/18/2024 12:00:00 PM
- Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor • Business Wire • 06/06/2024 11:00:00 AM
- CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results • Business Wire • 05/16/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 08:17:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/10/2024 01:04:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/09/2024 05:07:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/09/2024 01:19:04 PM
- CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer • Business Wire • 05/08/2024 01:00:00 PM
- CEL-SCI Appoints Mario Gobbo to Its Board of Directors • Business Wire • 04/23/2024 01:00:00 PM
- CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology • Business Wire • 03/19/2024 01:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/07/2024 04:33:42 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/07/2024 04:33:13 PM
- CEL-SCI Corporation Issues Letter to Shareholders • Business Wire • 03/06/2024 01:45:00 PM
- CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results • Business Wire • 02/15/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:31:12 PM
- CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock • Business Wire • 02/13/2024 05:00:00 PM
- CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock • Business Wire • 02/09/2024 01:30:00 PM
- CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug • Business Wire • 02/06/2024 02:00:00 PM
- European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine® • Business Wire • 01/31/2024 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 02:06:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 02:03:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 02:00:11 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 12/22/2023 09:01:06 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM